Some of the things that caught my eye in the annual report: - Biomarkers for cancer. Status update: Proof-of-concept study completed, clinical validation pending. In-licensing discussions underway. Proteomics International is in discussion with a preeminent Australian medical research institute to in-license a novel mass spectrometry-based cancer diagnostic test. The Company will provide further details as this develops. - The Australian Research Council Centre for Personalised Therapeutics Technologies is a $3.1 million Federally funded Industrial Transformation Training Centre (ITTC) in which Proteomics International is working alongside leading university-based researchers to apply the PromarkerTM technology to Complementary Diagnostics. Proteomics International is in advanced discussion with other consortium members for a discovery project in an area of significant unmet medical need. The Company will provide further details as this develops. - JP Morgan has 2m shares & Altor Alpha Fund has 800k shares in PIQ... good to see more institutional interest!
PIQ Price at posting:
54.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)